Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD) will host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss fourth-quarter results for the period ended December 31, 2025 and recent business progress.

Participant dial-ins are provided for US and international callers, and a replay will be available in the Investors section of the Relmada website.

News Market Reaction – RLMD

-2.69%

4 alerts

-2.69% News Effect

+7.1% Peak Tracked

-$13M Valuation Impact

$473M Market Cap

0.1x Rel. Volume

On the day this news was published, RLMD declined 2.69%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $473M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings call date: March 19, 2026 Earnings call time: 4:30 PM ET US dial-in: 1-877-407-0792 +3 more

6 metrics

Earnings call date March 19, 2026 Fourth quarter 2025 results conference call

Earnings call time 4:30 PM ET Start time for Q4 2025 results call

US dial-in 1-877-407-0792 Participant dial-in number (US)

International dial-in 1-201-689-8263 Participant dial-in number (International)

Quarter reported Fourth quarter 2025 Period ending December 31, 2025

Quarter end date December 31, 2025 End of reporting period for upcoming results

Market Reality Check

Price: $6.10 Vol: Volume 2,008,142 vs 20-da...

low vol

$6.10 Last Close

Volume Volume 2,008,142 vs 20-day average 2,958,394 (relative volume 0.68) ahead of the call announcement. low

Technical Shares at $6.32 are flagged as trading above the 200-day MA of $2.47 while still 15.85% below the 52-week high $7.51.

Peers on Argus

RLMD was down 4.53% while momentum scanners only flagged biotech peer CUE up 2.4...

1 Up

RLMD was down 4.53% while momentum scanners only flagged biotech peer CUE up 2.40% with no news, and broader peers in the watchlist showed mixed moves. This points to a stock-specific setup rather than a synchronized sector rotation ahead of the earnings-date event.

Previous Earnings date Reports

1 past event · Latest: Nov 07 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Nov 07	Earnings date notice	Neutral	+1.5%	Announced date and time for Q3 2025 earnings call and webcast.

Pattern Detected

Limited history: the last earnings-date scheduling headline saw a modest +1.53% 24-hour move.

Recent Company History

Over recent months, Relmada issued several value-defining updates, including positive Phase 2 NDV-01 bladder cancer data and an oversubscribed $160.0M private placement, alongside conference participation and regulatory alignment with the FDA. Against this backdrop, the current announcement simply schedules fourth quarter 2025 results and a business update call on March 19, 2026. Historically, the one prior earnings-date scheduling notice produced a modest +1.53% move, suggesting such logistics updates have had limited direct impact versus clinical and financing news.

Historical Comparison

+1.5% avg move · Prior earnings-date scheduling news for RLMD produced an average 24-hour move of 1.53%, indicating t...

earnings date

+1.5%

Average Historical Move earnings date

Prior earnings-date scheduling news for RLMD produced an average 24-hour move of 1.53%, indicating these logistical announcements have historically driven only modest trading shifts.

Current release continues the pattern of pre-announcing quarterly earnings calls, following a similar Q3 2025 earnings-date notice last November.

Market Pulse Summary

This announcement sets the timing for Relmada’s fourth quarter 2025 results and business update on M...

Analysis

This announcement sets the timing for Relmada’s fourth quarter 2025 results and business update on March 19, 2026, providing a clear near-term checkpoint after recent clinical and financing developments. Investors may focus on how management discusses NDV-01’s Phase 3 plans, integration of the recent $160.0M capital raise, and overall cash runway. Upcoming disclosures on R&D priorities and spending will be important alongside headline financial metrics.

Key Terms

central nervous system disorders

1 terms

central nervous system disorders medical

"a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders"

Conditions that affect the brain and spinal cord, such as diseases that disrupt thinking, movement, sensation or mood, are grouped as central nervous system (CNS) disorders. Investors watch them because they represent large, persistent medical needs and potential markets for drugs, devices and therapies; like underserved neighborhoods waiting for new infrastructure, successful treatments can create steady revenue streams or sharply alter a company’s prospects.

AI-generated analysis. Not financial advice.

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress.

Conference Call and Webcast Information:

• Date: Thursday, March 19, 2026 at 4:30 PM ET
• Participant Dial-in (US): 1-877-407-0792
• Participant Dial-in (International): 1-201-689-8263
• Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

FAQ

When will Relmada (RLMD) report Q4 2025 financial results and host the conference call?

Relmada will host the Q4 2025 results call on March 19, 2026 at 4:30 PM ET. According to the company, the call will cover financial results for the quarter ended December 31, 2025 and recent business progress, followed by a Q&A session.

How can investors access the Relmada (RLMD) March 19, 2026 webcast and replay?

Investors can join the live webcast via the Relmada investor website and access a replay afterward. According to the company, the replay will be posted in the Investors section at https://www.relmada.com/investors/ir-calendar for on-demand viewing.

What dial-in numbers does Relmada (RLMD) provide for the March 19, 2026 conference call?

Relmada provided participant dial-ins: US callers can use 1-877-407-0792; international callers can use 1-201-689-8263. According to the company, those numbers are for joining the March 19, 2026 call at 4:30 PM ET to discuss Q4 2025 results.

What topics will Relmada (RLMD) discuss on the March 19, 2026 earnings call?

Relmada will discuss fourth-quarter financial results for the period ended December 31, 2025 and recent business progress. According to the company, the call will cover financial performance and updates on its clinical-stage programs in oncology and CNS disorders.

Where can I find the replay of Relmada's (RLMD) March 19, 2026 webcast after the call?

The webcast replay will be posted in the Investors section of Relmada's website at the IR calendar page. According to the company, investors can access the replay at https://www.relmada.com/investors/ir-calendar after the live event concludes.

Is there a Q&A opportunity during the Relmada (RLMD) March 19, 2026 conference call?

Yes, the company indicated the call will discuss results and recent progress, implying a Q&A portion for participants. According to the company, the live conference call format typically includes a management presentation followed by questions from analysts and investors.